Effects of Canagliflozin on microbiota and glycometabolism, kidney function of patients with diabetic nephropathy

Trial Profile

Effects of Canagliflozin on microbiota and glycometabolism, kidney function of patients with diabetic nephropathy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 27 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top